• Alzamend Neuro plans a virtual annual shareholder meeting on Oct. 19, 2026.
• Shareholders will vote to elect six directors to serve until the 2028 annual meeting.
• Ballots also cover auditor ratification for the fiscal year ending Apr. 30, 2027.
• Investors will decide on converting Series D convertible preferred stock into common stock under a financing of up to USD 25 million.
• An additional proposal seeks authorization to adjourn the meeting to allow more time to solicit votes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-26-011083), on August 28, 2026, and is solely responsible for the information contained therein.